Search

Displaying results 1481 - 1490 of 1709 in total
  1. Target

    Glycine receptors

    go.drugbank.com/bio_entities/BE0009666
    TargetHumans

    Subunit of heteromeric glycine-gated chloride channels (PubMed:14551753, PubMed:23994010, PubMed:25730860, PubMed:37821459). Plays an important role in the down-regulation of neuronal excitability (PubMed:8298642, PubMed:9009272). Contri...

    Polypeptides: Glycine receptor subunit alpha-1, Glycine receptor subunit betaSynonyms: Glycine receptor 48 kDa subunit, Glycine receptor 58 kDa subunit
  2. Drug

    Caprospinol

    go.drugbank.com/drugs/DB05263
    Experimental

    Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.

  3. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259182,L46217,L46222] Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge.

  4. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]

  5. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist … Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).

  6. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug

  7. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).

  8. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%. Virtually all steps of the EBOV l...

  9. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    [A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.

  10. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].